20 results on '"Yin, Yongmei"'
Search Results
2. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
3. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
4. Efficacy and safety of margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
5. The role of TGF-β pathway alterations in immune regulation as a potential pan-cancer biomarker in immunotherapy
6. Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients
7. Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials
8. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
9. Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer—a narrative review
10. Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease
11. Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)
12. Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
13. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
14. Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China
15. An advanced refractory breast cancer patient with human epidermal growth factor receptor 2 discordance: a case report
16. Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024.
17. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.
18. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR + HER2 - metastatic breast cancer.
19. Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition).
20. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.